Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
Table 1
Baseline demographic, clinical, and biochemical characteristics.
Variable
Total n = 103 (%)
Age, years (mean, SD)
56.0 ± 13.0
Gender (male %)
55 (55.4)
Anthropometric characteristics
Weight, kg (median, IQR)
75.5 (68.4; 91.7)
Height, m (mean, SD)
1.64 ± 0.10
Waist, cm (mean, SD)
103.0 ± 14.0
Body mass index, kg/m2 (median, IQR)
28.46 (26.53; 31.84)
Clinical characteristics
SBP, mmHg (median, IQR)
125.0 (112.0; 140.0)
DBP, mmHg (median, IQR)
76.0 (69.0; 81.0)
Heart rate, bpm (median, IQR)
72.0 (65.0; 82.0)
Respiratory rate, bpm (median, IQR)
18.0 (17.0; 18.0)
Temperature, ° C (median, IQR)
36.5 (35.2; 36.7)
Biochemical characteristics
Glucose (mg/dL)
113.0 (93.0; 172.0)
Urea (mg/dL)
32.0 (27.4; 38.0)
Creatinine (mg/dL)
0.85 (0.68; 1.01)
Total cholesterol (mg/dL)
199.1 ± 60.1
HDL cholesterol (mg/dL)
38.9 (33.0; 47.0)
Non-HDL cholesterol (mg/dL)
154.2 ± 59.2
LDL cholesterol (mg/dL)
119.0 (75.4; 143.6)
VLDL cholesterol (mg/dL)
34.0 (22.0; 52.0)
Triglycerides (mg/dL)
219 (126.0; 336.0)
Atherogenic Index
0.75 (0.43; 0.94)
Sodium (mmol/L)
138.5 ± 2.8
Potassium (mmol/L)
4.4 (4.1; 4.6)
Chloride (mmol/L)
103.5 ± 2.4)
Aspartate aminotransferase (U/L)
22.0 (18.0; 26.0)
Alanine aminotransferase (U/L)
26.0 (18.0; 35.0)
Alkaline phosphatase (U/L)
86.0 (66.0; 109.7)
Gamma glutamyl transpeptidase (U/L)
34.5 (20.0; 46.0)
Total creatine kinase (U/L)
80.0 (62.0; 122.0)
Iron (g/dL)
91.1 (70.0; 114.0)
Transferrin (mg/dL)
259.0 ± 41.0
Erythrocytes (10^6/µL)
5.0 ± 0.6
Hemoglobin (g/dL)
15.1 ± 1.7
Platelets
(10^3/µl)
Leukocytes (10^3/µL)
7.1 ± 1.8
Cardiac C-reactive protein (mg/dL)
2.28 (0.83; 5.32)
Treatment dose
Rosuvastatin 10/ezetimibe 10 mg
68.0 (66.0)
Rosuvastatin 20/ezetimibe 10 mg
35.0 (34.0)
Type of dyslipidemia
Hypertriglyceridemia
13.0 (12.6)
Hypercholesterolemia
18.0 (17.5)
Mixed
59.0 (57.3)
Years of progression (median, IQR)
3.1 (1.5; 9.1)
Body mass index
Normal weight
8.0 (7.8)
Overweight
51.0 (49.5)
Obesity degree I
22.0 (21.4)
Obesity degree II
7.0 (6.8)
Morbid obesity
4.0 (3.9)
Globorisk, %
9.81 ± 5.89
Comorbidities
Diabetes
57.0 (55.3)
Arterial hypertension
58.0 (56.3)
Heart diseases
12.0 (11.7)
Alcohol
41.0 (39.8)
Smoking
9 (8.7)
Cardiovascular risk
Low risk
14 (15.2)
Moderate risk
12 (13.0)
High risk
45 (48.9)
Very-high risk
21 (22.8)
Glomerular filtration rate
97.0 (80.0; 105.0)
Concomitant medications
64.0 (62.1)
Number of medications per patient
2.0 (0.0; 4.0)
Abbreviations: HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very-low-density lipoprotein; SBP: systolic blood pressure; DBP: diastolic blood pressure; CRP: C-reactive protein; bpm: beats per minute or breaths per minute; kg: kilograms; cm: centimeters; mmHg: millimeters of mercury; mg: milligrams; dl: deciliter; U/L: international units per liter; µL: microliters. Triglycerides results for two patients were omitted because they represented extreme data (1,474 and 3141 mg/dL). Data were available to calculate cardiovascular risk from 92 patients and from 99 patients to calculate the GFR (glomerular filtration rate). The PAHO/WHO—PAHO calculator was used.
